Abstract YO19
Case summary
Recent studies have shown evidence of cross-lineage transdifferentiation of B-cell lymphomas, such as low-grade FL and CLL/SLL,to histiocytic and dendritic cell sarcomas, but the clonal relationship between the 2 neoplasms is still unclear. Here, we report the morphologic, molecular and cytogenetic analysis of a unique case of CLL/SLL associated with indeterminate dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm , using immunohistochemistry, electron microscopy, in situ hybridization and FISH.A 48-year-old Chinese female presented with left upper neck swelling. Blood examination revealed lymphocytosis.Microscopic examinations showed the lymph node has effaced architecture, and has a very complicated, variegated appearance with three distinct components. The first component contained small lymphocytes, prolymphocytes and paraimmunoblasts, showing typical CLL/SLL immunophenotype, with ZAP-70 positive and EBV negative. The second component contained nodular aggregates of large pink cells with abundant eosinophilic cytoplasm and deeply grooved nuclei, showing immunophenotype of indeterminate dendritic cell tumor and EBV positive. The third component had intermediate morphologic features between lymphoid cells and dendritic cells characteristics, a bit reminiscent of anaplastic large cell lymphoma, but expressed some B cell markers PAX5 and OCT2, as well as dendritic/histiocytic markers CD1a, CD68, Fascin, and Lysozyme, and was diffusely EBV positive. Electron microscopy revealed the cells in the third component had short and thick bulges like dendritic cell. FISH analysis using CLL probes showed identical deletion 17p13.1, deletion 11q22.3, and deletion 13q14.3 in all 3 components. Sharing of CD5 and OCT2 expression and identical cytogenetic abnormality in all 3 components suggest a common clonal origin for the three components.Our study provides evidence for transdifferentiation of CLL/SLL to dendritic cell tumor possibly via the intermediate linklymplymphodendritic cell neoplasm, and suggests that EBV may play a role in this phenomenon.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract